Drugs face cost-effectiveness trial after study approves cholesterol busters

THE health service is spending €90 million a year on cholesterol-lowering drugs for non-medical card holders — but the good news is they represent value for money.

Drugs face cost-effectiveness trial after study approves cholesterol busters

A major study found that the drugs, known as statins, pass the cost-effectiveness test when it comes to curing the patient without killing the taxpayer.

Now every newly available drug is to be put through a similar test before being subsidised under the Community Drugs Scheme, while many available under the scheme will be assessed.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €130 €65

Best value

Monthly €12€6 / month

More in this section

Lunchtime News

Newsletter

Keep up with stories of the day with our lunchtime news wrap and important breaking news alerts.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited